Skin Tight: Dermatology Specialty Leo Pharma To Buy Peplin for $287.5 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
The dermatology market is increasingly attractive for deal makers, as Leo's all-cash acquisition of Peplin demonstrates.
You may also be interested in...
Leo Pharma Aims To Extend Reach Of Dermatology Business With Global Expansion And Picato’s Green Light For Europe
Danish dermatology specialist Leo Pharma is hunting for new pipeline assets after its next major product – Picato gel – got the green light from Europe’s top regulator.
LEO Plays Up Rapid Action Of Picato For Actinic Keratosis
Newly approved plant-based gel works in just a few days of treatment, rather than the weeks required for some competitors.
LEO Pharma Pays $1 Billion To Get Its Psoriasis Drugs Back From Warner Chilcott
American dermatology dream: Danish specialty pharma plans to establish beachhead up in New Jersey after buying back U.S. rights.